Core Insights - Atossa Therapeutics supports the U.S. Surgeon General's Advisory linking alcohol consumption to increased breast cancer risk, emphasizing the need for public awareness and education on this issue [1][3][5] Industry Insights - Alcohol consumption is responsible for nearly 100,000 cancer cases and approximately 20,000 cancer deaths annually in the U.S., making it the third leading preventable cause of cancer after tobacco and obesity [2] - Breast cancer accounts for about 44,180 alcohol-related cases in women each year, representing approximately 16.4% of all breast cancer diagnoses [2] - The Advisory indicates that the risk of breast cancer begins to rise with the consumption of as little as one drink per day, yet only 45% of Americans believe alcohol significantly affects cancer development [3][4] Company Initiatives - Atossa Therapeutics is committed to advancing therapies aimed at reducing breast cancer burden and supports public policies that inform and protect women's health [5] - The company has released a video to further educate the public about the Surgeon General's Advisory and its implications for breast cancer [4] - Atossa advocates for updating health warning labels on alcoholic beverages, expanding public education efforts, and incorporating alcohol reduction strategies into cancer prevention initiatives [8]

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium SEATTLE, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, Sweden. The data, which will be ...

Common Stock, $0.18 par value ATOS The Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 | --- | --- | |------- ...

Exhibit 99.1 Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factor • Released a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)- endoxifen which met the primary endpoint with 95 percent (19/20 patients) ...

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted ...

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today released positive topline data from the KARISMA-Endoxifen Phase 2 study of (Z)-endoxifen in premenopausal women with mammographic breast density (MBD). The ...

SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Interes ...

SEATTLE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its recognition and support of Breast Cancer Awareness Month this October; highlighting the importance of increasing awareness, advancing research, and driving progress toward innovative treatments for breast cancer. Approximately one in eight women will be diagnosed with breast cancer in their lifetime, so this annual campaign serves as a powerful reminder of the ongoing need for ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Atossa Genetics Inc. is one of 1016 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 differen ...

Core Viewpoint - Atossa Therapeutics supports the FDA's final rule to update mammography regulations, which aims to improve breast cancer detection by requiring facilities to inform patients about breast density in understandable terms [1][2][3] Group 1: Regulatory Impact - The FDA's final rule is a significant advancement in breast cancer detection and patient outcomes, as breast density is an independent risk factor for developing breast cancer [2] - The regulation is expected to enhance early breast cancer detection by notifying women with dense breast tissue, allowing for informed discussions about supplemental screening options like ultrasound or MRI [2] Group 2: Company Initiatives - Atossa is evaluating its lead asset, (Z)-endoxifen, in multiple phase 2 clinical trials, including the Karisma-Endoxifen study, which aims to reduce mammographic breast density in premenopausal women [3][6] - The company is supporting the SMART study, a phase 2 trial to validate an AI-driven breast cancer risk assessment model, which could lead to a future phase 3 trial for (Z)-endoxifen in breast cancer prevention [4] Group 3: Product Development - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that shows efficacy in patients resistant to other hormonal treatments and targets oncogenic proteins [5] - Atossa is developing an oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity, showing good tolerance in early studies [6] Group 4: Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for significant unmet medical needs in oncology, particularly in breast cancer [7]